Goldman Sachs has upgraded BioNTech SE (NASDAQ:BNTX), citing the company’s BNT327, an immuno-oncology asset in clinical ...

Fintel reports that on November 8, 2024, Goldman Sachs upgraded their outlook for BioNTech SE - Depositary Receipt () ...

Option chain shows key data for BioNTech's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for ...

Stock futures are quiet this morning, following a busy week that brought in a new President elect, a subsequent market rally, and an interest rate cut from the Federal Reserve. The Dow Jones ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.53, ...

In a report released yesterday, Chris Shibutani from Goldman Sachs upgraded BioNTech SE (BNTX – Research Report) to a Buy, with a price ...

Market Reaction: Big Pharma's vaccine names dipped on Wednesday with Moderna, Inc. (NASDAQ:MRNA) ending the day down 2.78%, ...

Meanwhile, among the sector's biggest decliners were hospital operators, with HCA Healthcare Inc.'s stock (HCA) shedding 4.6%, Universal Health Services Inc. shares (UHS) falling 3.7% and shares of ...

Harding Loevner International Developed Markets Equity composite rose 10.0% gross of fees in the third quarter. Click here to ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

BioNTech SE (BNTX) reports strong revenue growth and pipeline progress, while navigating financial and legal hurdles.

Jefferies analyst Akash Tewari maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $150.00.